Neutral
NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II
NanoViricides, Inc. has filed its Quarterly Report for the fiscal quarter ending March 31, 2026, and is advancing its lead drug candidate, NV-387, tow...